Cellular Biomedicine Group Appoints Director of Medical Research

PALO ALTO, Calif., July 11, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Maxwell Wang, M.D., PhD, as Director of Medical Research.

Dr. Wang received his MD degree from Wuerzburg University in Germany and PhD degree from University of Aberdeen, UK, following which he continued extensive research at the University of Connecticut Health Center. During his academia Dr. Wang was the first to find the paracrine and autocrine effects of CCN family genes (genes relating to connective tissue growth) in bone cell differentiation and the capability of  bone marrow-derived CTGF-GFP cells to increase bone formation. Dr. Wang is an orthopedic surgeon with over 10 years of experience in academic research focused on mesenchymal stem cells and bone cells.

Dr. Chase Dai, VP and GM of CBMG's Autologous Products Business Unit, commented, "Dr. Wang's extensive experience in the field of stem cells, particularly as applied to orthopedics, will be a valuable asset to our Knee Osteoarthritis program which is currently in clinical trial."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
[email protected]

SOURCE Cellular Biomedicine Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED